Wire
Orchestra BioMed Gets Second FDA Breakthrough Designation for Hypertension Therapy
Orchestra BioMed (OBIO) said Thursday the US Food and Drug Administration granted a second Breakthrough Device designation for its atrioventricular interval modulation therapy.The designation covers patients with uncontrolled hypertension despite the use of antihypertensive medications, including those who are indicated for a pacemaker.Orchestra BioMed has a collaboration with Medtronic (MDT) to develop and commercialize the therapy for pacemaker-indicated patients, according to the statement.Price: $3.79, Change: $-0.01, Percent Change: -0.21%
$MDT$OBIO
